Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Mayday University Hospital awarded 3 stars in NHS performance rating

4
August 2005

View Articles

First studies underway at Mayday University Hospital!

16
June 2005

View Articles

Richmond Becomes the UK's First CRO to be Based in 2 Acute NHS Teaching Hospitals

3
May 2005

View Articles

Head of Data Management completes the London Marathon

19
April 2005

View Articles

Additional Holter and Telemetry Equipment Introduced

7
January 2005

View Articles

Richmond Pharmacology visits Japan to expand business

5
January 2005

View Articles

Latest news

Richmond Pharmacology Appoints Patrick Ramiah as Director of Clinical Project Delivery & Operational Excellence

September 1, 2025
Richmond Pharmacology is delighted to announce the promotion of Patrick Ramiah to the role of Director of Clinical Project Delivery & Operational Excellence, effective from 1 September 2025.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event